Kallistatin, a new and reliable biomarker for the diagnosis of liver cirrhosis

Acta Pharmaceutica Sinica B

Volumn 5, Issue 3, 2015, Pages 194-200

  Cheng, Zhiyun ^a,b   Lv, Yinghui ^a,b   Pang, Suqiu ^a,b   Bai, Ruyu ^a,b   Wang, Mingxi ^a,b   Lin, Shuyu ^a,b   Xu, Tianwen ^c   Spalding, Duncan ^d   Habib, Nagy ^d   Xu, Ruian ^a,b  

^a HUAQIAO UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c FUJIAN MEDICAL UNIVERSITY   (China)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Biomarker; Hepatocellular carcinoma; Kallistatin; Liver cirrhosis; Liver fibrosis

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BIOLOGICAL MARKER; KALLISTATIN; LAMIVUDINE; PROTEIN; TELBIVUDINE; UNCLASSIFIED DRUG;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALCOHOL LIVER CIRRHOSIS; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEALTH STATUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; RELIABILITY; VIRAL LIVER CIRRHOSIS;

EID: 84947202830     PISSN: 22113835     EISSN: 22113843     Source Type: Journal    
DOI: 10.1016/j.apsb.2015.02.003     Document Type: Article

References (39)

1. Benvegnu L, Gios M, Boccato S, Alberti A. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 2004, 53:744-749.
2. Nord HJ. Biopsy diagnosis of cirrhosis: blind percutaneous versus guided direct vision techniques-a review. Gastrointest Endosc 1982, 28:102-104.
3. Chao JL, Yin H, Yao YY, Shen B, Smith RS, Chao L. Novel role of kallistatin in protection against myocardial ischemia-reperfusion injury by preventing apoptosis and inflammation. Hum Gene Ther 2006, 17:1201-1213.
4. Gao L, Yin H, S Smith R, Chao L, Chao J Role of kallistatin in prevention of cardiac remodeling after chronic myocardial infarction. Lab Invest 2008, 88:1157-1166.
5. Miao RQ, Agata J, Chao L, Chao J. Kallistatin is a new inhibitor of angiogenesis and tumor growth. Blood 2002, 100:3245-3252.
6. Wang CR, Chen SY, Wu CL, Liu MF, Jin YT, Chao L Prophylactic adenovirus-mediated human kallistatin gene therapy suppresses rat arthritis by inhibiting angiogenesis and inflammation. Arthritis Rheum 2005, 52:1319-1324.
7. Chao JL, Schmaier A, Chen LM, Yang ZR, Chao L. Kallistatin a novel human tissue kallikrein inhibitor: levels in body fluids, blood cells, and tissues in health and disease. J Lab Clin Med 1996, 127:612-620.
8. Wolf WC, Harley RA, Sluce D, Chao L, Chao J. Localization and expression of tissue kallikrein and kallistatin in human blood vessels. J Histochem Cytochem 1999, 47:221-228.
9. Chen VC, Chao L, Pimenta DC, Bledsoe G, Juliano L, Chao J. Identification of a major heparin-binding site in kallistatin. J Biol Chem 2001, 276:1276-1284.
10. Wolf WC, Harley RA, Sluce D, Chao L, Chao J. Cellular localization of kallistatin and tissue kallikrein in human pancreas and salivary glands. Histochem Cell Biol 1998, 110:477-484.
11. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994, 107:1103-1109.
12. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001, 121:91-100.
13. Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, et al. Liver fibrosis in overweight patients. Gastroenterology 2000, 118:1117-1123.
14. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005, 115:209-218.
15. Poynard T, Yuen MF, Ratzin V, Lai CL. Viral hepatitis C. Lancet 2003, 362:2095-2100.
16. Freeman RB, Steffick DE, Guidinger MK, Farmer DG, Berg CL, Merion RM. Liver and intestine transplantation in the United States, 1997-2006. Am J Transplant 2008, 8:958-976.
17. Arthur MJ. Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C. Gastroenterology 2002, 122:1525-1528.
18. Dienstag JL, Goldin RD, Heathcote EJ, Hann HW, Woessner M, Stephenson SL, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003, 124:105-117.
19. Hui CK, Leung N, Shek TW, Yao H, Lee WK, Lai JY, et al. Sustained disease remission after spontaneous HBeAg seroconversion is associated with reduction in fibrosis progression in chronic hepatitis B Chinese patients. Hepatology 2007, 46:690-698.
20. Kweon YO, Goodman ZD, Dienstag JL, Schiff ER, Brown NA, Burchardt E, et al. Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. J Hepatol 2001, 35:749-755.
21. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002, 122:1303-1313.
22. Serpaggi J, Carnot F, Nalpas B, Canioni D, Guéchot J, Lebray P, et al. Direct and indirect evidence for the reversibility of cirrhosis. Hum Pathol 2006, 37:1519-1526.
23. Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, et al. Histological improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000, 132:517-524.
24. Farci P, Roskams T, Chessa L, Peddis G, Mazzoleni AP, Scioscia R, et al. Long-term benefit of interferon a therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology 2004, 126:1740-1749.
25. Dufour JF, DeLellis R, Kaplan MM. Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann Intern Med 1997, 127:981-985.
26. Dixon JB, Bhathal PS, Hughes NR, O'Brien PE. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology 2004, 39:1647-1654.
27. Wakim-Fleming J, Mullen KD. Long-term management of alcoholic liver disease. Clin Liver Dis 2005, 9:135-149.
28. Xu R, Harrison PM, Chen M, Li L, Tsui TY, Fung PC, et al. Cytoglobin overexpression protects against damage-induced fibrosis. Mol Ther 2006, 13:1093-1100.
29. Chai KX, Chen LM, Chao J, Chao L. Kallistatin: a novel human serine proteinase inhibitor. Molecular cloning, tissue distribution, and expression in Escherichia coli. J Biol Chem 1993, 268:24498-24505.
30. Chao J, Chao L. Biochemistry, regulation and potential function of kallistatin. Biol Chem Hoppe-Seyler 1995, 376:705-713.
31. Chao J, Miao RQ, Chen V, Chen LM, Chao L. Novel roles of kallistatin, a specific tissue kallikrein inhibitor, in vascular remodeling. Biol Chem 2001, 382:15-21.
32. Hsieh JL, Shen PC, Shiau AL, Jou IM, Lee CH, Teo ML, et al. Adenovirus-mediated kallistatin gene transfer ameliorates disease progression in a rat model of osteoarthritis induced by anterior cruciate ligament transection. Hum Gene Ther 2009, 20:147-158.
33. Shen B, Chao L, Chao J. Pivotal role of JNK-dependent FOXO1 activation in downregulation of kallistatin expression by oxidative stress. Am J Physiol Heart Circ Physiol 2010, 298:H1048-H1054.
34. Shen B, Hagiwara M, Yao YY, Chao L, Chao JL Salutary effect of kallistatin in salt-induced renal injury, inflammation, and fibrosis via antioxidative stress. Hypertension 2008, 51:1358-1365.
35. Yin H, Gao L, Shen B, Chao L, Chao J. Kallistatin inhibits vascular inflammation by antagonizing tumor necrosis factor-α-induced nuclear factor κB activation. Hypertension 2010, 56:260-267.
36. Thongboonkerd V, Gozal E, Sachleben LR, Arthur JM, Pierce WM, Cai J, et al. Proteomic analysis reveals alterations in the renal kallikrein pathway during hypoxia-induced hypertension. J Biol Chem 2002, 277:34708-34716.
37. 4-induced injury by intramuscular electrotransfer of a kallistatin-encoding plasmid. World J Gastroenterol 2011, 17:111-117.
38. Jenkins AJ, McBride JD, Januszewski AS, Karschimkus CS, Zhang B, O'Neal DN., et al. Increased serum kallistatin levels in type 1 diabetes patients with vascular complications. J Angiogenes Res 2010, 2:19-26.
39. Lin WC, Lu SL, Lin CF, Chen CW, Chao L, Chao J, et al. Plasma kallistatin levels in patients with severe community- acquired pneumonia. Crit Care 2013, 17:R27-R36.